Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides calories for metabolic processes, restoring blood glucose levels and reducing protein and fat catabolism. Sodium chloride maintains osmolarity and replaces sodium and chloride losses.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Parenteral source of carbohydrates and electrolytes,Treatment of fluid and electrolyte depletion,Maintenance fluid therapy,Correction of hypovolemia
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Intravenous infusion. Adult: 500-1000 m L per dose at a rate of 2-6 m L/min, frequency dependent on fluid and electrolyte needs. Maximum 40 m L/kg/day.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Glucose half-life is approximately 1.5-2 hours in normal individuals, prolonged in renal impairment or diabetes. Sodium and chloride have no defined half-life as they are electrolytes; their elimination depends on renal function and hydration status.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Dextrose is metabolized via glycolysis and the citric acid cycle; insulin-dependent uptake. Sodium chloride is not metabolized; excreted renally.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Renal: >99% of administered glucose is metabolized or excreted; sodium and chloride are excreted renally. In dextrose 5% and sodium chloride 0.2%, glucose undergoes metabolism to CO2 and water; excess is excreted renally. Sodium and chloride are almost entirely excreted renally with >90% reabsorption under normal conditions.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Glucose: negligible (<1%). Sodium and chloride: not protein bound.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Glucose: approximately 0.2-0.25 L/kg; distributes primarily in extracellular fluid. Sodium: 0.6-0.7 L/kg (total body water); chloride: similar. Clinical meaning: initial distribution reflects ECF volume; changes indicate fluid shifts.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Intravenous: 100% for all components. Not applicable for oral or other routes as this formulation is for IV use only.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
For GFR 30-50 m L/min: close monitoring of electrolytes; GFR <30 m L/min: use with caution, monitor for hypernatremia and fluid overload, reduce infusion rate by 50%.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No specific adjustment required for Child-Pugh class A or B; use with caution in class C due to risk of fluid overload.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Intravenous infusion. 5-10 m L/kg per dose as needed; rate not to exceed 0.5-1 g/kg/hour of dextrose. For neonates, avoid unless specific indication due to high sodium load.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Reduce initial infusion rate to 1-2 m L/min due to decreased renal function and higher risk of fluid overload; monitor serum sodium and osmolality closely.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
Solutions containing dextrose may be contraindicated in patients with known allergies to corn or corn products. Intrathecal administration is contraindicated.
None
Risk of hyperglycemia and hyperosmolar syndrome, especially in patients with diabetes mellitus,May cause fluid and solute overload leading to dilution of serum electrolytes, overhydration, congested states, or pulmonary edema,Use with caution in patients with heart failure, renal impairment, or severe dehydration,Not for use in patients with intracranial or intraspinal hemorrhage,Air embolism risk if administered via pressurized IV lines
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hyperglycemia and hyperosmolar coma,Hypersensitivity to corn or corn products,Intrathecal administration,Severe dehydration with hypernatremia,Addison's disease without adequate corticosteroid therapy
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No specific food interactions. Monitor fluid and electrolyte balance especially if patient is on a low-sodium diet. Dextrose may affect blood glucose; adjust meal timing or insulin accordingly.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Dextrose and sodium chloride are physiologic substances. No teratogenic risk is reported; however, hyperglycemia or electrolyte imbalances in the mother may affect the fetus. Use standard precautions.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Dextrose and sodium chloride are normal blood constituents; transfer into breast milk is not clinically significant. No M/P ratio available; considered safe during breastfeeding.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Total body water increases in pregnancy, potentially expanding distribution volume; however, dosing is based on clinical status. Monitor for fluid overload and electrolyte disturbances. No specific dose adjustment is required for standard maintenance infusions.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
This isotonic solution provides 170 kcal/L from dextrose and is used for maintenance hydration and electrolyte replacement. Monitor serum glucose in diabetics; may cause hyperglycemia. Contains 34 m Eq/L sodium and 34 m Eq/L chloride. Avoid in patients with hypernatremia, fluid overload, or significant renal impairment. Use with caution in pediatric and elderly patients due to risk of hyponatremia.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
This solution provides sugar and salt to help maintain body fluids and energy.,Tell your healthcare provider if you have diabetes, heart failure, kidney disease, or are on a low-salt diet.,Report any swelling, shortness of breath, headache, nausea, or changes in urination.,Do not drink this solution; it is given intravenously.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides calories for metabolic processes, restoring blood glucose levels and reducing protein and fat catabolism. Sodium chloride maintains osmolarity and replaces sodium and chloride losses.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is: Intravenous infusion. Adult: 500-1000 m L per dose at a rate of 2-6 m L/min, frequency dependent on fluid and electrolyte needs. Maximum 40 m L/kg/day.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose and sodium chloride are physiologic substances. No teratogenic risk is reported; however, hyperglycemia or electrolyte imbalances in the mother may affect the fetus. Use s. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.